AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

CVRx, Inc.

$2.88 -$4.22 (-59.44%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$2.86
Day Range
$2.75$2.9
Year Range
$2.2$11.3
Market Cap
76.42M
AVG Volume
657.54K
Trailing/Forward PE
-1.45/-
PEG ratio
0.38
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
NASDAQUS
Revenue (USD)
020M40M60M202020212022202320242025
CVRX Revenue (USD) by year
PeriodRevenue (USD)
202556.65M
202451.29M
202339.3M
202222.47M
202113.04M
20206.05M
Net Income (USD)
-60M-40M-20M0202020212022202320242025
CVRX Net Income (USD) by year
PeriodNet Income (USD)
2025-53.31M
2024-59.97M
2023-41.2M
2022-41.43M
2021-43.08M
2020-14.11M
Operating Income (USD)
-60M-40M-20M0202020212022202320242025
CVRX Operating Income (USD) by year
PeriodOperating Income (USD)
2025-51.27M
2024-59.49M
2023-43.1M
2022-42.53M
2021-25.97M
2020-11.51M
EBITDA (USD)
-60M-40M-20M0202020212022202320242025
CVRX EBITDA (USD) by year
PeriodEBITDA (USD)
2025-46.74M
2024-54.89M
2023-38.73M
2022-40.74M
2021-40.6M
2020-11.48M
Cash Flows (USD)
-60M-40M-20M0202020212022202320242025
CVRX Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-40.75M
2024-40.51M
2023-39.61M
2022-43.36M
2021-28.91M
2020-16.41M
EPS (USD)
-60-40-200202020212022202320242025
CVRX EPS (USD) by year
PeriodEPS (USD)
2025-2.05
2024-2.69
2023-1.98
2022-2.02
2021-49.77
2020-28.44
Expenses (USD)
050M100M150MR&DSG&ACapex202020212022202320242025
CVRX Expenses (USD) by year
PeriodExpenses (USD)
202599.8M
2024103.81M
202376.73M
202260.68M
202136.55M
202016.44M
Cash & Debt (USD)
050M100M150MCashLong Term Debt202020212022202320242025
CVRX Cash & Debt (USD) by year
PeriodCash & Debt (USD)
202575.71M
2024105.93M
202390.57M
2022106.19M
2021142.07M
202059.11M
Debt ratios
00.20.40.6202320242025
CVRX Debt ratios by year
PeriodDebt ratios
20250.14
20240.32
20230.46
Margins
0%25%50%75%100%202020212022202320242025
CVRX Margins by year
PeriodMargins
202584.65%
202483.75%
202384.08%
202277.75%
202172.08%
202076.21%
Return on Capital
-150%-100%-50%0%50%202020212022202320242025
CVRX Return on Capital by year
PeriodReturn on Capital
2025-135.56%
2024-84.39%
2023-54.25%
2022-37.94%
2021-29.51%
20204.81%
Shares Outstanding
010M20M30M202020212022202320242025
CVRX Shares Outstanding by year
PeriodShares Outstanding
202526.22M
202422.6M
202320.6M
202220.5M
202120.36M
2020360.12K
Book Value Per Share (USD)
-1000-750-500-2500250202020212022202320242025
CVRX Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20251.5
20243.14
20233.69
20225.33
20217.17
2020-814.28
Total Assets (USD)
050M100M150M200M202020212022202320242025
CVRX Total Assets (USD) by year
PeriodTotal Assets (USD)
2025104.79M
2024133.41M
2023115.23M
2022124.94M
2021152.55M
202064.78M
Employee Count
010020030020212022202320242025
CVRX Employee Count by year
PeriodEmployee Count
2025223
2024206
2023200
2022160
2021109
Free Cash Flow Yield
-80%-60%-40%-20%0%med -20.05%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-53.76%
Sep 26-50.76%
Aug 26-52.48%
Aug 26-54.52%
Aug 26-50.27%
Aug 26-64.78%
Jul 26-29.41%
Jul 26-32.14%
Jul 26-31.03%
Jul 26-28.06%
Jul 26-27.21%
Jun 26-26%
Jun 26-30.78%
Jun 26-30.29%
Jun 26-28.32%
May 26-27.3%
May 26-24.94%
May 26-25.44%
May 26-22.76%
May 26-19.5%
Apr 26-20.13%
Apr 26-21.12%
Apr 26-21.71%
Apr 26-17.25%
Mar 26-17.44%
Mar 26-17.89%
Mar 26-20.64%
Mar 26-18.84%
Feb 26-19.05%
Feb 26-25.44%
Feb 26-31.4%
Feb 26-22.74%
Jan 26-21.75%
Jan 26-20.38%
Jan 26-28.59%
Jan 26-18.37%
Jan 26-20.98%
Dec 25-20.08%
Dec 25-18.55%
Dec 25-17.63%
Dec 25-16.46%
Nov 25-15.19%
Nov 25-15.12%
Nov 25-16.07%
Nov 25-15.34%
Oct 25-14.84%
Oct 25-14.47%
Oct 25-15.2%
Oct 25-16.9%
Oct 25-17.36%
Sep 25-20.03%
Sep 25-21.09%
Sep 25-19.22%
Sep 25-19.34%
Aug 25-19.26%
Aug 25-19.39%
Aug 25-21.51%
Aug 25-20.89%
Aug 25-21.25%
Jul 25-19.26%
Jul 25-20.08%
Jul 25-23.52%
Jul 25-24.42%
Jun 25-27.61%
Jun 25-27.42%
Jun 25-27.42%
Jun 25-24.49%
May 25-24.2%
May 25-24.09%
May 25-25.34%
May 25-33.68%
May 25-22.55%
Apr 25-26.64%
Apr 25-28.68%
Apr 25-28.77%
Apr 25-15.29%
Mar 25-14.35%
Mar 25-14.35%
Mar 25-15.67%
Mar 25-15.49%
Feb 25-13.83%
Feb 25-12.94%
Feb 25-11.77%
Feb 25-12.13%
Jan 25-11.11%
Jan 25-9.99%
Jan 25-10.08%
Jan 25-12.53%
Jan 25-13.02%
Dec 24-13.48%
Dec 24-14.66%
Dec 24-13.84%
Dec 24-13.17%
Nov 24-11.59%
Nov 24-11.96%
Nov 24-12.76%
Nov 24-11.44%
Nov 24-13.25%
Oct 24-17.53%
Oct 24-18.6%
Price to Sales
0246810med 3.69Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Price to Sales by year
PeriodPrice to Sales
Sep 261.25
Sep 261.32
Aug 261.28
Aug 261.23
Aug 261.33
Aug 261.04
Jul 262.31
Jul 262.11
Jul 262.19
Jul 262.42
Jul 262.5
Jun 262.61
Jun 262.21
Jun 262.24
Jun 262.4
May 262.49
May 262.73
May 262.67
May 263.16
May 263.69
Apr 263.57
Apr 263.41
Apr 263.31
Apr 264.17
Mar 264.12
Mar 264.02
Mar 263.48
Mar 263.82
Feb 263.78
Feb 262.83
Feb 262.29
Feb 263.06
Jan 263.2
Jan 263.42
Jan 262.44
Jan 263.79
Jan 263.32
Dec 253.47
Dec 253.75
Dec 253.95
Dec 254.23
Nov 254.59
Nov 254.61
Nov 254.33
Nov 254.54
Oct 254.86
Oct 254.99
Oct 254.75
Oct 254.27
Oct 254.16
Sep 253.6
Sep 253.42
Sep 253.75
Sep 253.73
Aug 253.74
Aug 253.72
Aug 253.35
Aug 253.45
Aug 253.7
Jul 254.08
Jul 253.92
Jul 253.34
Jul 253.22
Jun 252.85
Jun 252.87
Jun 252.87
Jun 253.21
May 253.25
May 253.26
May 253.1
May 252.33
May 253.5
Apr 252.96
Apr 252.75
Apr 252.74
Apr 255.16
Mar 255.5
Mar 255.5
Mar 255.04
Mar 255.1
Feb 255.71
Feb 256.1
Feb 257.28
Feb 257.06
Jan 257.7
Jan 258.57
Jan 258.5
Jan 256.83
Jan 256.58
Dec 246.35
Dec 245.84
Dec 246.19
Dec 246.5
Nov 247.39
Nov 247.16
Nov 246.71
Nov 247.48
Nov 246.46
Oct 244.91
Oct 244.62
Price to Book
02468med 4.26Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Price to Book by year
PeriodPrice to Book
Sep 263.83
Sep 264.05
Aug 263.92
Aug 263.77
Aug 264.09
Aug 263.18
Jul 264.69
Jul 264.29
Jul 264.45
Jul 264.92
Jul 265.07
Jun 265.31
Jun 264.48
Jun 264.55
Jun 264.87
May 265.05
May 265.53
May 265.42
May 264.55
May 265.31
Apr 265.15
Apr 264.91
Apr 264.77
Apr 266.01
Mar 265.94
Mar 265.79
Mar 265.02
Mar 265.5
Feb 265.44
Feb 264.07
Feb 263.3
Feb 263.57
Jan 263.73
Jan 263.98
Jan 262.84
Jan 264.42
Jan 263.87
Dec 254.04
Dec 254.37
Dec 254.6
Dec 254.93
Nov 255.34
Nov 255.36
Nov 255.05
Nov 255.29
Oct 254.59
Oct 254.7
Oct 254.48
Oct 254.03
Oct 253.92
Sep 253.4
Sep 253.23
Sep 253.54
Sep 253.52
Aug 253.53
Aug 253.51
Aug 253.16
Aug 253.26
Aug 252.82
Jul 253.11
Jul 252.98
Jul 252.55
Jul 252.45
Jun 252.17
Jun 252.19
Jun 252.19
Jun 252.45
May 252.48
May 252.49
May 252.37
May 251.78
May 252.53
Apr 252.14
Apr 251.99
Apr 251.98
Apr 253.73
Mar 253.97
Mar 253.97
Mar 253.64
Mar 253.68
Feb 254.12
Feb 254.4
Feb 255.27
Feb 255.12
Jan 255.59
Jan 256.21
Jan 256.16
Jan 254.95
Jan 254.77
Dec 244.6
Dec 244.23
Dec 244.48
Dec 244.71
Nov 245.35
Nov 245.19
Nov 244.86
Nov 245.42
Nov 244.68
Oct 243.94
Oct 243.72
CVRx, Inc.
CVRX
Stockpicker

Video analysis: CVRX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CVRX

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

prnewswire.com · 10 Sep 2026

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX).

CVRx Secures Devoted Health Coverage for Barostim Therapy

zacks.com · 28 Aug 2026

CVRx Secures Devoted Health Coverage for Barostim Therapy

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims

prnewswire.com · 27 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims

On Behalf of Investors of CVRx, Inc. - CVRX NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

prnewswire.com · 26 Aug 2026

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

globenewswire.com · 25 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CVRx Responds to Letter from Pointillist Family Office

globenewswire.com · 25 Aug 2026

CVRx Responds to Letter from Pointillist Family Office

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx's Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026: The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input and appreciates the open dialogue the Company has maintained with Mr.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.